secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001493152-24-039300
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MangoRx launches oral Tirzepatide weight loss tablet 'TRIM' at $399/month
-------------------------------------------------------------------------

- TRIM is a compounded oral dissolvable Tirzepatide tablet priced at $399 per month.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist; clinical trials showed up to 20% weight loss in 72 weeks.
- TRIM complements existing oral Semaglutide product (SLIM), offering two GLP-1 options.
- Global GLP-1 market projected to grow from $49.3B (2024) to $157.5B by 2035 per Roots Analysis.
- Available by prescription via MangoRx telemedicine platform; targets non-injectable weight loss demand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224039300/0001493152-24-039300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224039300/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer